HLB Life Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:33 am EST
Share
HLB Life Science Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 334.1 million compared to KRW 270.67 million a year ago. Net loss was KRW 16,314.83 million compared to net income of KRW 11,469.17 million a year ago. Basic loss per share from continuing operations was KRW 160 compared to basic earnings per share from continuing operations of KRW 113.1503 a year ago. Diluted loss per share from continuing operations was KRW 160 compared to diluted earnings per share from continuing operations of KRW 113.1503 a year ago. Basic loss per share was KRW 160 compared to basic earnings per share of KRW 119 a year ago.
For the nine months, sales was KRW 1,050.7 million compared to KRW 471.06 million a year ago. Net loss was KRW 12,435.85 million compared to net income of KRW 7,696.4 million a year ago. Basic loss per share from continuing operations was KRW 122 compared to basic earnings per share from continuing operations of KRW 77.0183 a year ago. Diluted loss per share from continuing operations was KRW 122 compared to diluted earnings per share from continuing operations of KRW 77.0183 a year ago. Basic loss per share was KRW 122 compared to basic earnings per share of KRW 81 a year ago.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB LIFE SCIENCE CO., LTD. 
